{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:46:46Z","timestamp":1787168806046,"version":"build-2736575974"},"reference-count":18,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,1]]},"abstract":"<jats:title>\n                    <jats:bold>ABSTRACT<\/jats:bold>\n                  <\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>We report a 35-year-old female receiving natalizumab as monotherapy for multiple sclerosis who subsequently developed severe cytomegalovirus gastritis. As cytomegalovirus gastritis has not been previously described during natalizumab treatment, we discuss the biological plausibility of this potential association and avenues for further study.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.14309\/crj.2017.43","type":"journal-article","created":{"date-parts":[[2017,3,16]],"date-time":"2017-03-16T15:24:43Z","timestamp":1489677883000},"page":"e43","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Severe Cytomegalovirus Gastritis During Natalizumab-Mediated Immunosuppression"],"prefix":"10.14309","volume":"4","author":[{"given":"Stephen P.","family":"Persaud","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adil","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anjum","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tariq","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-43-20260710","doi-asserted-by":"crossref","first-page":"379","DOI":"10.4253\/wjge.v2.i11.379","article-title":"Cytomegalovirus gastritis.","volume":"2","author":"Hokama","year":"2010","journal-title":"World J Gastrointest Endosc"},{"key":"R2-43-20260710","doi-asserted-by":"crossref","first-page":"924","DOI":"10.7326\/0003-4819-119-9-199311010-00010","article-title":"Gastrointestinal cytomegalovirus disease.","volume":"119","author":"Goodgame","year":"1993","journal-title":"Ann Intern Med"},{"key":"R3-43-20260710","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/S1473-3099(04)01202-2","article-title":"Human cytomegalovirus: Clinical aspects, immune regulation, and emerging treatments.","volume":"4","author":"Gandhi","year":"2004","journal-title":"Lancet Infect Dis"},{"key":"R4-43-20260710","doi-asserted-by":"crossref","first-page":"e1001256","DOI":"10.1371\/journal.ppat.1001256","article-title":"HCMV spread and cell tropism are determined by distinct virus populations.","volume":"7","author":"Scrivano","year":"2011","journal-title":"PLoS Pathog"},{"key":"R5-43-20260710","first-page":"1108","article-title":"Pseudotumoral appearance of cytomegalovirus esophagitis and gastritis in AIDS patients.","volume":"88","author":"Laguna","year":"1993","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"R6-43-20260710","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1111\/den.12044","article-title":"Polypoid change in cytomegalovirus gastritis following treatment.","volume":"25","author":"Tsujii","year":"2013","journal-title":"Dig Endosc"},{"key":"R7-43-20260710","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.5858\/2008-132-1586-PATTPD","article-title":"Practical approach to the pathologic diagnosis of gastritis.","volume":"132","author":"Sepulveda","year":"2008","journal-title":"Arch Pathol Lab Med"},{"key":"R8-43-20260710","first-page":"296","article-title":"Cytomegalovirusassociated protein losing gastropathy in an immunocompetent adult: A case report.","volume":"70","author":"Setakhr","year":"2007","journal-title":"Acta Gastroenterol Belg"},{"key":"R9-43-20260710","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1016\/j.transproceed.2006.05.067","article-title":"Postural epigastric pain as a sign of CMV gastritis: A case report.","volume":"38","author":"Moustafellos","year":"2006","journal-title":"Transplant Proc"},{"key":"R10-43-20260710","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/S0016-5085(99)70079-X","article-title":"Evolution of acute cytomegalovirus gastritis to chronic gastrointestinal dysmotility in a nonimmunocompromised adult.","volume":"116","author":"Nowak","year":"1999","journal-title":"Gastroenterology"},{"key":"R11-43-20260710","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/j.1365-2559.1991.tb01460.x","article-title":"Cytomegalovirus gastritis with perforation and gastrocolic fistula formation.","volume":"18","author":"Aqel","year":"1991","journal-title":"Histopathology"},{"key":"R13-43-20260710","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.tips.2015.09.006","article-title":"PML: The dark side of immunotherapy in multiple sclerosis.","volume":"36","author":"Warnke","year":"2015","journal-title":"Trends Pharmocol Sci"},{"key":"R14-43-20260710","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.jneuroim.2007.04.006","article-title":"Expert opinion: Guidelines for the use of natalizumab in multiple sclerosis patients previously treated with immunomodulating therapies.","volume":"187","author":"Gold","year":"2007","journal-title":"J Neuroimmunol"},{"key":"R15-43-20260710","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1177\/1756285612470401","article-title":"Best practice in the use of natalizumab in multiple sclerosis.","volume":"6","author":"Fernandez","year":"2013","journal-title":"Ther Adv Neurol Disord"},{"key":"R17-43-20260710","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1093\/cid\/cit376","article-title":"Central nervous system herpes simplex and varicella zoster virus infections in natalizumabtreated patients.","volume":"57","author":"Fine","year":"2013","journal-title":"Clin Infect Dis"},{"key":"R18-43-20260710","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1093\/ecco-jcc\/jjv226","article-title":"Vedolizumab effectiveness and safety over the first year of use in an IBD clinical practice.","volume":"10","author":"Vivio","year":"2016","journal-title":"J Crohns Colitis"},{"key":"R19-43-20260710","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1046\/j.1365-2249.2002.01984.x","article-title":"Increased expression of mucosal addressin cell adhesion molecule-1 (MAdCAM-1) and lymphocyte recruitment in murine gastritis induced by Helicobacter pylori.","volume":"130","author":"Hatanaka","year":"2002","journal-title":"Clin Exp Immunol"},{"key":"R20-43-20260710","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.3748\/wjg.v9.i12.2701","article-title":"Expression of mucosal addressin cell adhesion molecule 1 on vascular endothelium of gastric mucosa in patients with nodular gastritis.","volume":"9","author":"Ohara","year":"2003","journal-title":"World J Gastroenterol"}],"container-title":["ACG Case Reports Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/02075970-201704000-00043","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T14:20:21Z","timestamp":1786544421000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/02075970-201704000-00043"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.14309\/crj.2017.43","relation":{},"ISSN":["2326-3253"],"issn-type":[{"value":"2326-3253","type":"print"}],"subject":[],"published":{"date-parts":[[2017,1]]}}}